1型糖尿病器官捐献者胰腺β细胞中HLA II类分子表达上调
该研究对来自nPOD的非糖尿病(n=5)、自身抗体阳性(Aab+,n=5)和1型糖尿病(n=5)捐献者的胰腺组织切片进行HLA-II、CD68和胰岛素免疫染色,共分析7415个胰岛、338480个细胞,并用共聚焦显微镜确认。1型糖尿病供者含胰岛素胰岛的HLA-II阳性面积百分比为24.31%,高于胰岛素缺乏胰岛的0.67%、非糖尿病供者的3.80%和Aab+供者的2.31%。体外实验显示促炎细胞因子可诱导健康人胰岛HLA-II和HLA-I表达上调。
要点
- 1型糖尿病供者含胰岛素胰岛HLA-II阳性面积为24.31%,高于非糖尿病供者的3.80%和Aab+供者的2.31%。
- 1型糖尿病供者含胰岛素胰岛中27.65%的β细胞同时表达HLA-II和胰岛素,非糖尿病和Aab+供者分别为0.96%和0.59%。
- 促炎细胞因子处理可使人离体胰岛和重组人胰岛微组织的HLA-II和HLA-I表达上调。
核心结论
- 研究提供了明确证据表明1型糖尿病患者的胰腺β细胞可表达HLA-II。
- 促炎细胞因子可在体外诱导健康人离体胰岛或重组人胰岛中HLA-II表达上调。
- 表达HLA-II的β细胞可能成为自身反应性CD4+淋巴细胞的直接靶点,支持HLA-II在1型糖尿病发病中的作用。
研究设计与样本
- 研究对来自胰腺器官捐献者网络(nPOD)的非糖尿病(n=5)、自身抗体阳性(Aab+,n=5)和1型糖尿病(n=5)捐献者的胰腺组织切片进行HLA-II、CD68和胰岛素免疫染色。
- 共分析7415个胰岛、包含338480个细胞,并用Zeiss激光扫描共聚焦显微镜(LSM880)对301个随机选择的胰岛进行高分辨率成像确认。
- 体外培养健康人离体胰岛和重组人胰岛微组织,用不同浓度的促炎细胞因子(IFN-γ、TNF-α和IL-1β)处理,检测葡萄糖刺激的胰岛素分泌及HLA-I和HLA-II表达。
主要发现
- 1型糖尿病供者含胰岛素胰岛的HLA-II阳性面积百分比为24.31%,高于1型糖尿病胰岛素缺乏胰岛的0.67%、非糖尿病供者的3.80%和Aab+供者的2.31%。
- 1型糖尿病供者含胰岛素胰岛中,45.89%的总胰岛素信号与HLA-II共定位,27.65%的胰岛β细胞同时表达HLA-II和胰岛素;非糖尿病和Aab+供者分别有0.96%和0.59%的胰岛β细胞同时表达这两种标志物。
- 1型糖尿病供者β细胞中HLA-II主要存在于细胞质,与胰岛素共定位。
- 在人离体胰岛和重组人胰岛实验中,促炎细胞因子刺激后胰岛素分泌发生变化,与培养基对照相比HLA-II和HLA-I表达更高,且HLA-I和HLA-II RNA转录本上调。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: We aimed to characterise and quantify the expression of HLA class II (HLA-II) in human pancreatic tissue sections and to analyse its induction in human islets. METHODS: We immunostained human pancreatic tissue sections from non-diabetic (n = 5), autoantibody positive (Aab+; n = 5), and type 1 diabetic (n = 5) donors, obtained from the Network of Pancreatic Organ Donors (nPOD), with HLA-II, CD68 and insulin. Each tissue section was acquired with a widefield slide scanner and then analysed with QuPath software. In total, we analysed 7415 islets that contained 338,480 cells. Widefield microscopy was further complemented by high resolution imaging of 301 randomly selected islets, acquired using a Zeiss laser scanning confocal (LSM880) to confirm our findings. Selected beta cells were acquired in enhanced resolution using LSM880 with an Airyscan detector. Further, we cultured healthy isolated human islets and reaggregated human islet microtissues with varying concentrations of proinflammatory cytokines (IFN-γ, TNF-α and IL-1β). After proinflammatory cytokine culture, islet function was measured by glucose-stimulated insulin secretion, and HLA-I and HLA-II expression was subsequently evaluated with immunostaining or RNA sequencing. RESULTS: Insulin-containing islets (ICIs) of donors with type 1 diabetes had a higher percentage of HLA-II positive area (24.31%) compared with type 1 diabetic insulin-deficient islets (IDIs, 0.67%), non-diabetic (3.80%), and Aab+ (2.31%) donors. In ICIs of type 1 diabetic donors, 45.89% of the total insulin signal co-localised with HLA-II, and 27.65% of the islet beta cells expressed both HLA-II and insulin, while in non-diabetic and Aab+ donors 0.96% and 0.59% of the islet beta cells, respectively, expressed both markers. In the beta cells of donors with type 1 diabetes, HLA-II was mostly present in the cell cytoplasm, co-localising with insulin. In the experiments with human isolated islets and reaggregated human islets, we observed changes in insulin secretion upon stimulation with proinflammatory cytokines, as well as higher expression of HLA-II and HLA-I when compared with controls cultured with media, and an upregulation of HLA-I and HLA-II RNA transcripts. CONCLUSIONS/INTERPRETATION: After a long-standing controversy, we provide definitive evidence that HLA-II can be expressed by pancreatic beta cells from patients with type 1 diabetes. Furthermore, this upregulation can be induced in vitro in healthy isolated human islets or reaggregated human islets by treatment with proinflammatory cytokines. Our findings support a role for HLA-II in type 1 diabetes pathogenesis since HLA-II expressing beta cells can potentially become a direct target of autoreactive CD4+ lymphocytes.
引用
- Quesada-Masachs E, Zilberman S, Rajendran S, et al. Upregulation of HLA class II in pancreatic beta cells from organ donors with type 1 diabetes. Diabetologia. 2021. PMID: 34932134. doi:10.1007/s00125-021-05619-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。